Psychosocial functioning in women with premenstrual dysphoric disorder before and after treatment with sertraline or placebo

Teri B. Pearlstein, Uriel Halbreich, Evan D. Batzar, Candace Brown, Jean Endicott, Ellen Frank, Ellen W. Freeman, Wilma M. Harrison, Roger F. Haskett, Anna L. Stout, Kimberly A. Yonkers

Research output: Contribution to journalArticle

139 Citations (Scopus)

Abstract

Background: The objective of this study was to evaluate the pretreatment psychosocial functioning of women with premenstrual dysphoric disorder (PMDD) and the effect of sertraline treatment on psychosocial functioning in these patients. Method: Two hundred forty-three women recruited from 12 university- affiliated sites and meeting DSM-IV criteria for PMDD completed 1 cycle of single-blind placebo and were randomly assigned to flexible dose sertraline or placebo for 3 cycles. Psychosocial functioning was assessed by the Daily Record of Severity of Problems (DRSP), the Social Adjustment Scale (SAS), and the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q). Results: SAS scores during the follicular phase were similar to SAS scores of community norms, whereas the pretreatment SAS and Q-LES-Q scores during the luteal phase were similar to scores of women with depressive disorders. Sertraline was significantly more effective than placebo in improving psychosocial functioning as measured by the SAS, the Q-LES-Q, and the 3 DRSP items of impaired productivity, interference with social activities, and interference with relationships with others. Improvement in psychosocial functioning assessed by SAS and Q-LES-Q correlated with improvement in symptomatology assessed by the Clinical Global Impressions-Improvement (CGI- I) scale and the Hamilton Rating Scale for Depression (HAM-D). Remitters (CGI-I score of 1) were more likely to function better at baseline and showed larger improvements in functioning and quality of life with treatment compared with nonremitters. Conclusion: Sertraline was superior to placebo in improving psychosocial functioning in women with PMDD as reflected by SAS, Q- LES-Q, and DRSP measures. Functional improvement correlated with improvement in premenstrual symptomatology and was apparent by the second cycle of treatment. Comparison of pretreatment SAS scores in women with PMDD with the scores of other populations of women documents the degree of luteal phase functional impairment in women with PMDD and a relative absence of follicular phase impairment.

Original languageEnglish (US)
Pages (from-to)101-109
Number of pages9
JournalJournal of Clinical Psychiatry
Volume61
Issue number2
DOIs
StatePublished - Jan 1 2000

Fingerprint

Social Adjustment
Sertraline
Placebos
Quality of Life
Follicular Phase
Luteal Phase
Therapeutics
Premenstrual Dysphoric Disorder
Depressive Disorder
Diagnostic and Statistical Manual of Mental Disorders
Depression
Surveys and Questionnaires

All Science Journal Classification (ASJC) codes

  • Psychiatry and Mental health

Cite this

Psychosocial functioning in women with premenstrual dysphoric disorder before and after treatment with sertraline or placebo. / Pearlstein, Teri B.; Halbreich, Uriel; Batzar, Evan D.; Brown, Candace; Endicott, Jean; Frank, Ellen; Freeman, Ellen W.; Harrison, Wilma M.; Haskett, Roger F.; Stout, Anna L.; Yonkers, Kimberly A.

In: Journal of Clinical Psychiatry, Vol. 61, No. 2, 01.01.2000, p. 101-109.

Research output: Contribution to journalArticle

Pearlstein, TB, Halbreich, U, Batzar, ED, Brown, C, Endicott, J, Frank, E, Freeman, EW, Harrison, WM, Haskett, RF, Stout, AL & Yonkers, KA 2000, 'Psychosocial functioning in women with premenstrual dysphoric disorder before and after treatment with sertraline or placebo', Journal of Clinical Psychiatry, vol. 61, no. 2, pp. 101-109. https://doi.org/10.4088/JCP.v61n0205
Pearlstein, Teri B. ; Halbreich, Uriel ; Batzar, Evan D. ; Brown, Candace ; Endicott, Jean ; Frank, Ellen ; Freeman, Ellen W. ; Harrison, Wilma M. ; Haskett, Roger F. ; Stout, Anna L. ; Yonkers, Kimberly A. / Psychosocial functioning in women with premenstrual dysphoric disorder before and after treatment with sertraline or placebo. In: Journal of Clinical Psychiatry. 2000 ; Vol. 61, No. 2. pp. 101-109.
@article{55c38f87d438454cb0461c53594dab95,
title = "Psychosocial functioning in women with premenstrual dysphoric disorder before and after treatment with sertraline or placebo",
abstract = "Background: The objective of this study was to evaluate the pretreatment psychosocial functioning of women with premenstrual dysphoric disorder (PMDD) and the effect of sertraline treatment on psychosocial functioning in these patients. Method: Two hundred forty-three women recruited from 12 university- affiliated sites and meeting DSM-IV criteria for PMDD completed 1 cycle of single-blind placebo and were randomly assigned to flexible dose sertraline or placebo for 3 cycles. Psychosocial functioning was assessed by the Daily Record of Severity of Problems (DRSP), the Social Adjustment Scale (SAS), and the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q). Results: SAS scores during the follicular phase were similar to SAS scores of community norms, whereas the pretreatment SAS and Q-LES-Q scores during the luteal phase were similar to scores of women with depressive disorders. Sertraline was significantly more effective than placebo in improving psychosocial functioning as measured by the SAS, the Q-LES-Q, and the 3 DRSP items of impaired productivity, interference with social activities, and interference with relationships with others. Improvement in psychosocial functioning assessed by SAS and Q-LES-Q correlated with improvement in symptomatology assessed by the Clinical Global Impressions-Improvement (CGI- I) scale and the Hamilton Rating Scale for Depression (HAM-D). Remitters (CGI-I score of 1) were more likely to function better at baseline and showed larger improvements in functioning and quality of life with treatment compared with nonremitters. Conclusion: Sertraline was superior to placebo in improving psychosocial functioning in women with PMDD as reflected by SAS, Q- LES-Q, and DRSP measures. Functional improvement correlated with improvement in premenstrual symptomatology and was apparent by the second cycle of treatment. Comparison of pretreatment SAS scores in women with PMDD with the scores of other populations of women documents the degree of luteal phase functional impairment in women with PMDD and a relative absence of follicular phase impairment.",
author = "Pearlstein, {Teri B.} and Uriel Halbreich and Batzar, {Evan D.} and Candace Brown and Jean Endicott and Ellen Frank and Freeman, {Ellen W.} and Harrison, {Wilma M.} and Haskett, {Roger F.} and Stout, {Anna L.} and Yonkers, {Kimberly A.}",
year = "2000",
month = "1",
day = "1",
doi = "10.4088/JCP.v61n0205",
language = "English (US)",
volume = "61",
pages = "101--109",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "2",

}

TY - JOUR

T1 - Psychosocial functioning in women with premenstrual dysphoric disorder before and after treatment with sertraline or placebo

AU - Pearlstein, Teri B.

AU - Halbreich, Uriel

AU - Batzar, Evan D.

AU - Brown, Candace

AU - Endicott, Jean

AU - Frank, Ellen

AU - Freeman, Ellen W.

AU - Harrison, Wilma M.

AU - Haskett, Roger F.

AU - Stout, Anna L.

AU - Yonkers, Kimberly A.

PY - 2000/1/1

Y1 - 2000/1/1

N2 - Background: The objective of this study was to evaluate the pretreatment psychosocial functioning of women with premenstrual dysphoric disorder (PMDD) and the effect of sertraline treatment on psychosocial functioning in these patients. Method: Two hundred forty-three women recruited from 12 university- affiliated sites and meeting DSM-IV criteria for PMDD completed 1 cycle of single-blind placebo and were randomly assigned to flexible dose sertraline or placebo for 3 cycles. Psychosocial functioning was assessed by the Daily Record of Severity of Problems (DRSP), the Social Adjustment Scale (SAS), and the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q). Results: SAS scores during the follicular phase were similar to SAS scores of community norms, whereas the pretreatment SAS and Q-LES-Q scores during the luteal phase were similar to scores of women with depressive disorders. Sertraline was significantly more effective than placebo in improving psychosocial functioning as measured by the SAS, the Q-LES-Q, and the 3 DRSP items of impaired productivity, interference with social activities, and interference with relationships with others. Improvement in psychosocial functioning assessed by SAS and Q-LES-Q correlated with improvement in symptomatology assessed by the Clinical Global Impressions-Improvement (CGI- I) scale and the Hamilton Rating Scale for Depression (HAM-D). Remitters (CGI-I score of 1) were more likely to function better at baseline and showed larger improvements in functioning and quality of life with treatment compared with nonremitters. Conclusion: Sertraline was superior to placebo in improving psychosocial functioning in women with PMDD as reflected by SAS, Q- LES-Q, and DRSP measures. Functional improvement correlated with improvement in premenstrual symptomatology and was apparent by the second cycle of treatment. Comparison of pretreatment SAS scores in women with PMDD with the scores of other populations of women documents the degree of luteal phase functional impairment in women with PMDD and a relative absence of follicular phase impairment.

AB - Background: The objective of this study was to evaluate the pretreatment psychosocial functioning of women with premenstrual dysphoric disorder (PMDD) and the effect of sertraline treatment on psychosocial functioning in these patients. Method: Two hundred forty-three women recruited from 12 university- affiliated sites and meeting DSM-IV criteria for PMDD completed 1 cycle of single-blind placebo and were randomly assigned to flexible dose sertraline or placebo for 3 cycles. Psychosocial functioning was assessed by the Daily Record of Severity of Problems (DRSP), the Social Adjustment Scale (SAS), and the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q). Results: SAS scores during the follicular phase were similar to SAS scores of community norms, whereas the pretreatment SAS and Q-LES-Q scores during the luteal phase were similar to scores of women with depressive disorders. Sertraline was significantly more effective than placebo in improving psychosocial functioning as measured by the SAS, the Q-LES-Q, and the 3 DRSP items of impaired productivity, interference with social activities, and interference with relationships with others. Improvement in psychosocial functioning assessed by SAS and Q-LES-Q correlated with improvement in symptomatology assessed by the Clinical Global Impressions-Improvement (CGI- I) scale and the Hamilton Rating Scale for Depression (HAM-D). Remitters (CGI-I score of 1) were more likely to function better at baseline and showed larger improvements in functioning and quality of life with treatment compared with nonremitters. Conclusion: Sertraline was superior to placebo in improving psychosocial functioning in women with PMDD as reflected by SAS, Q- LES-Q, and DRSP measures. Functional improvement correlated with improvement in premenstrual symptomatology and was apparent by the second cycle of treatment. Comparison of pretreatment SAS scores in women with PMDD with the scores of other populations of women documents the degree of luteal phase functional impairment in women with PMDD and a relative absence of follicular phase impairment.

UR - http://www.scopus.com/inward/record.url?scp=0034008808&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034008808&partnerID=8YFLogxK

U2 - 10.4088/JCP.v61n0205

DO - 10.4088/JCP.v61n0205

M3 - Article

VL - 61

SP - 101

EP - 109

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 2

ER -